Medical technology company LivaNova PLC (Nasdaq: LIVN) declared on Monday that it has commenced the commercial launch of its Essenz Perfusion System in China, the company's second-largest market for heart-lung machines after the US.

The system, recently approved by China's National Medical Products Administration (NMPA), enables patient-tailored perfusion through data-driven decision-making, enhancing clinical workflows and patient care during cardiopulmonary bypass procedures.

China has approximately 330 million cardiovascular disease patients, with over 700 hospitals capable of cardiac surgery and an estimated 208,500 extracorporeal circulation procedures projected in 2025. Essenz is already available in Europe, Canada, Australia, Japan and the UAE, supporting over 100,000 patients globally since its February 2023 launch.

Developed with input from more than 300 perfusionists worldwide, the Essenz Perfusion System includes the next-generation Essenz HLM, Essenz Patient Monitor and Essenz In-Line Blood Monitor (ILBM), offering individual pump control and real-time data delivery to optimise patient safety and procedural accuracy.

LivaNova, headquartered in London, employs around 2,900 staff and provides advanced medical technologies in neurological and cardiac care across more than 100 countries.